{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-006353","form_type":"8-K","ticker":null,"cik":"0001603207","company_name":"Notable Labs, Ltd.","filed_at":"2023-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.793726+00:00","generated_at":"2026-06-18T18:01:14.606242+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Vascular Biogenics transfers listing to Nasdaq Capital Market; gets 180-day extension to meet bid price rule","bullets":["Transferred from Nasdaq Global Market to Nasdaq Capital Market effective March 2, 2023; symbol remains VBLT.","Received 180-day extension until August 28, 2023 to regain compliance with $1.00 minimum bid price.","Must have closing bid price of at least $1.00 for 10 consecutive business days during extension period.","Previously received deficiency notice on August 31, 2022 for bid price below $1.00 for 30 consecutive days."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-006353","json":"https://secwatch.observer/filing/0001493152-23-006353.json","markdown":"https://secwatch.observer/filing/0001493152-23-006353.md","text":"https://secwatch.observer/filing/0001493152-23-006353.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1603207/000149315223006353/0001493152-23-006353-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1603207/000149315223006353/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T18:01:14.606242+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"abd945f0d15e0ad9c58c71eb44b6d11a66669444","claim":"Notable Labs, Ltd. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)(ii)).","evidence_excerpt":"February 28, 2023, VBL received confirmation that Nasdaq had approved the Transfer, and VBL’s ordinary shares will begin trading on The Nasdaq Capital Market effective with the open of trading on March 2, 2023. VBL’s ordinary shares continue to trade under the symbol “VBLT”. The Nasdaq Capital Market operates in substantially the same manner as The Nasdaq Global Market, with issuers listed on The Nasdaq Capital Market tier required to meet certain financial and corporate governance requirements to qualify for continued listing. On February 28, 2023, VBL received confirmation that Nasdaq has de","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1603207/000149315223006353/0001493152-23-006353-index.htm","confidence":0.95,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"extension granted"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5450(a)(1), 5810(c)(3)(A)(ii)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}